Amgen and Simcere sign China biosimilars deal

Amgen and Chinese drugmaker Simcere Pharmaceutical Group have signed an exclusive agreement to co-develop and commercialize four biosimilars in China. The collaboration includes undisclosed biosimilars in the areas of inflammation and oncology.

The US biotech will remain responsible for the co-development, marketing approval applications and manufacturing of the biosimilars, which are part of its existing portfolio. Simcere will be responsible for distribution and commercialization in China, while Amgen will have a limited right to co-promote the products.